Professor Zhengming Chen
Professor of Epidemiology and Director of China Programmes
- MRC PHRU Programme Leader
- Clinical Trial Service Unit and Epidemiological Studies Unit
Professor Zhengming Chen qualified in medicine at Shanghai Medical University in 1983 (now Fudan University), and gained his DPhil in Epidemiology at the University of Oxford in 1993. He was appointed as Professor of Epidemiology by the University of Oxford in 2006. He is now the Director of the China Programs at the Oxford University’s Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and co-executive director of the China Oxford Centre for International Health Research. His main researches focus on the environmental and genetic causes of chronic disease, evidence-based medicine and evaluation of widely practicable treatments for chronic diseases (such as IHD, stroke and cancer) as well as efficient strategies for chronic disease control in developing countries. Over the past 20 years, he has led several large randomised trials in heart disease (eg, COMMIT/CCS-2), stroke (eg, CAST) and cancer and 3 cohort studies involving >750,000 individuals. Since 2003 he has been the lead principal investigator in the UK for the China Kadoorie Biobank (CKB) prospective study of 0.5 million adults. He leads a research team in Oxford which is responsible for study design and development of procedures and IT systems for the CKB, and for central data management, curation and detailed analyses. He is an honorary professor of Peking Union Medical College and Fudan University in China.
Independent and interactive associations of heart rate and body mass index or blood pressure with type 2 diabetes mellitus incidence: A prospective cohort study.
Xu C. et al, (2018), J Diabetes Investig
A review of lifestyle, metabolic risk factors and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
Pang Y. et al, (2018), J Gastroenterol Hepatol
[Associations between family history of major chronic diseases and healthy lifestyles in Chinese adults].
Zhu NB. et al, (2018), Zhonghua Liu Xing Bing Xue Za Zhi, 39, 1537 - 1543
Blood Pressure and Risk of Subarachnoid Hemorrhage in China.
McGurgan IJ. et al, (2018), Stroke
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz E. et al, (2018), Circulation, 138, 2499 - 2512